Daily Dose - Oct 23rd, 2026
Daily Dose |
View online
October 23, 2026
Lonza might not be in a capacity race, but Samsung Biologics is another case
The rival CDMOs are increasingly going head-to-head in key business areas, including high-volume mammalian production and antibody-drug conjugates.
Read More
Esteve invests $80M to expand API manufacturing in China
The new Shaoxing site adds 250 cubic meters of reactor capacity, with room for future expansion to more than 400 cubic meters.
Read More
ProBio completes pre-approval inspection at China biologics facility
The Nanjing site supported a customer program from investigational new drug development through biologics license application submission.
Read More
